Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb

Showing 15 posts of 146 posts found.

BMS building

Bristol-Myers Squibb enters academic R&D tie-up

November 4, 2015
Research and Development BMS, Bristol-Myers Squibb, Cardioxy, John Hopkins, acquisition, immunooncology, job losses

Bristol-Myers Squibb and The Johns Hopkins University have entered into a collaboration agreement, as part of the pharma firm’s rare …

News
Yervoy

FDA approves Bristol-Myers Squibb’s skin cancer drug

October 29, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilumumab, melanoma

The FDA has recommended Bristol-Myers Squibb’s cancer drug Yervoy (ipilimumab) for the adjuvant treatment of patients with melanoma. The drug, …

News

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
T-cell

$350m collaboration deal for BMS and Five Prime Therapeutics

October 15, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …

News
Opdivo

Bristol-Myers Squibb notches kidney cancer first with Opdivo

September 28, 2015
Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma

Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …

News

FDA grants Opdivo breakthrough status for kidney cancer

September 18, 2015
Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …

News

Bristol-Myers Squibb makes big pharma deals

September 1, 2015
Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis

Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …

News
Opdivo

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

August 12, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …

News

BMS to trial Opdivo in solid tumours

July 30, 2015
Research and Development BMS, Bristol-Myers Squibb, Kyowa Hakko Kirin, Poteligeo, mogamulizumab, nivolumab, opdivo, solid tumours

Bristol-Myers Squibb will begin early-phase trials of its immuno-oncology treatment Opdivo with other cancer treatments, to see if the combination …

News
Daklinza

NICE restricts access to new hepatitis C treatments

July 29, 2015
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C

NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …

News
Opdivo

BMS halts Opdivo kidney cancer trial early

July 22, 2015
Research and Development BMS, Bristol-Myers Squibb, European Commission, Kidney cancer, opdivo, renal cell carcinoma

Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after …

News

Opdivo launched in the UK for skin cancer

July 2, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer

Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …

News
Opdivo

BMS’ Opdivo improves lung cancer survival

May 29, 2015
Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo

A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …

News
Merck image

Conference round-up: companies go big on hepatitis C at EASL

April 29, 2015
Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza

Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …

News
Opdivo

EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026